Age and Referral Route Impact the Access to Diagnosis for Women with Advanced Ovarian Cancer

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE--5-a population-based study. Lancet Oncol. 2014;15(1):23–34. doi:10.1016/S1470-2045(13)70546-1
   PubMed Web of Science ®Google Scholar
• Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–296. doi:10.3322/caac.21456
   PubMed Web of Science ®Google Scholar
• Kossaï M, Leary A, Scoazec JY, Genestie C. Ovarian cancer: a heterogeneous disease. Pathobiology. 2018;85(1–2):41–49. doi:10.1159/000479006
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Shih IM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186(4):733–747. doi:10.1016/j.ajpath.2015.11.011
   PubMed Web of Science ®Google Scholar
• Hodgson A, Turashvili G. Pathology of hereditary breast and ovarian cancer. Front Oncol. 2020;10:531790. doi:10.3389/fonc.2020.531790
   PubMed Web of Science ®Google Scholar
• Hamilton W, Peters TJ, Bankhead C, Sharp D. Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. BMJ. 2009;339(aug25 2):b2998. doi:10.1136/bmj.b2998
   PubMedGoogle Scholar
• Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004;291(22):2705–2712. doi:10.1001/jama.291.22.2705
   PubMed Web of Science ®Google Scholar
• Jensen H, Tørring ML, Olesen F, Overgaard J, Vedsted P. Cancer suspicion in general practice, urgent referral and time to diagnosis: a population-based GP survey and registry study. BMC Cancer. 2014;14(1):636. doi:10.1186/1471-2407-14-636
   PubMedGoogle Scholar
• Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305(22):2295–2303. doi:10.1001/jama.2011.766
   PubMed Web of Science ®Google Scholar
• Ghose A, Bolina A, Mahajan I, et al. Hereditary ovarian cancer: towards a cost-effective prevention strategy. Int J Environ Res Public Health. 2022;19(19):12057. doi:10.3390/ijerph191912057
   PubMed Web of Science ®Google Scholar
• Olesen F, Hansen RP, Vedsted P. Delay in diagnosis: the experience in Denmark. Br J Cancer. 2009;101(Suppl S2):S5–S8. doi:10.1038/sj.bjc.6605383
   PubMedGoogle Scholar
• Prades J, Espinàs JA, Font R, Argimon JM, Borràs JM. Implementing a cancer fast-track programme between primary and specialised care in Catalonia (Spain): a mixed methods study. Br J Cancer. 2011;105(6):753–759. doi:10.1038/bjc.2011.308
   PubMed Web of Science ®Google Scholar
• Dilley J, Burnell M, Gentry-Maharaj A, et al. Ovarian cancer symptoms, routes to diagnosis and survival - population cohort study in the ‘no screen’ arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecol Oncol. 2020;158(2):316–322. doi:10.1016/j.ygyno.2020.05.002
   PubMed Web of Science ®Google Scholar
• Nagle CM, Francis JE, Nelson AE, et al. Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian ovarian cancer study group. J Clin Oncol. 2011;29(16):2253–2258. doi:10.1200/JCO.2010.32.2164
   PubMed Web of Science ®Google Scholar
• Altman AD, Lambert P, Love AJ, et al. Examining the effects of time to diagnosis, income, symptoms, and incidental detection on overall survival in epithelial ovarian cancer: Manitoba Ovarian Cancer Outcomes (MOCO) study group. Int J Gynecol Cancer. 2017;27(8):1637–1644. doi:10.1097/IGC.0000000000001074
   PubMed Web of Science ®Google Scholar
• Rai N, Nevin J, Downey G, et al. Outcomes following implementation of symptom triggered diagnostic testing for ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2015;187:64–69. doi:10.1016/j.ejogrb.2015.02.011
   PubMed Web of Science ®Google Scholar
• Gilbert L, Basso O, Sampalis J, et al. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncol. 2012;13(3):285–291. doi:10.1016/S1470-2045(11)70333-3
   PubMed Web of Science ®Google Scholar
• du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized Phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO) [German working group for gynecological oncology, study group for ovarian carcinoma (AGO-OVAR) and the French group of National Investigators for Ovarian Cancer Studies (GINECO)]. Cancer. 2009;115(6):1234–1244. doi:10.1002/cncr.24149
   PubMed Web of Science ®Google Scholar
• Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006;103(2):559–564. doi:10.1016/j.ygyno.2006.03.051
   PubMed Web of Science ®Google Scholar
• Confederation of Regional Cancer Centers. Standardiserat vårdförlopp ovarialcancer, epitelial [Cancer patient pathway for epithelial ovarian cancer]. Available from: https://kunskapsbanken.cancercentrum.se/diagnoser/aggstockscancer-epitelial/vardforlopp/. Accessed May 04, 2021. Swedish.
   Google Scholar
• Timmerman D, Valentin L, Bourne TH, et al. Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) group. Ultrasound Obstet Gynecol. 2000;16(5):500–505. doi:10.1046/j.1469-0705.2000.00287.x
   PubMed Web of Science ®Google Scholar
• Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990;97(10):922–929. doi:10.1111/j.1471-0528.1990.tb02448.x
   PubMedGoogle Scholar
• Team RC. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing V; 2017.
   Google Scholar
• Vandborg MP, Edwards K, Kragstrup J, Vedsted P, Hansen DG, Mogensen O. A new method for analyzing diagnostic delay in gynecological cancer. Int J Gynecol Cancer. 2012;22(5):712–717. doi:10.1097/IGC.0b013e31824c6d0e
   PubMed Web of Science ®Google Scholar
• Ingeman ML, Christensen MB, Bro F, Knudsen ST, Vedsted P. The Danish cancer pathway for patients with serious non-specific symptoms and signs of cancer-a cross-sectional study of patient characteristics and cancer probability. BMC Cancer. 2015;15:421. doi:10.1186/s12885-015-1424-5
   PubMed Web of Science ®Google Scholar
• Chan JK, Tian C, Kesterson JP, et al. Symptoms of women with high-risk early-stage ovarian cancer. Obstet Gynecol. 2022;139(2):157–162. doi:10.1097/AOG.0000000000004642
   PubMed Web of Science ®Google Scholar
• Baun ML, Jensen H, Falborg AZ, Heje HN, Petersen LK, Vedsted P. Ovarian cancer suspicion, urgent referral and time to diagnosis in Danish general practice: a population-based study. Fam Pract. 2019;36(6):751–757. doi:10.1093/fampra/cmz013
   PubMed Web of Science ®Google Scholar
• Funston G, Hamilton W, Abel G, Crosbie EJ, Rous B, Walter FM. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: a population-based cohort study. PLoS Med. 2020;17(10):e1003295. doi:10.1371/journal.pmed.1003295
   PubMed Web of Science ®Google Scholar
• Colombo N, Sessa C, Bois AD, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer. 2019;29(4):728–760. doi:10.1136/ijgc-2019-000308
   Web of Science ®Google Scholar